Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday

Syndax Pharmaceuticals (NASDAQ:SNDX) is anticipated to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.66) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX opened at $19.69 on Monday. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. Syndax Pharmaceuticals has a 1-year low of $8.58 and a 1-year high of $22.73. The business has a 50 day simple moving average of $20.85 and a two-hundred day simple moving average of $17.78. The stock has a market capitalization of $1.71 billion, a PE ratio of -5.45 and a beta of 0.46.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,410 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $71,712.30. Following the sale, the chief financial officer owned 140,429 shares in the company, valued at $2,953,221.87. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael A. Metzger sold 17,159 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the sale, the chief executive officer owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 30,063 shares of company stock worth $628,332. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its stake in Syndax Pharmaceuticals by 478.8% in the 1st quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock worth $4,637,000 after acquiring an additional 312,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after purchasing an additional 3,094 shares during the period. Caxton Associates LLP bought a new position in Syndax Pharmaceuticals in the first quarter worth approximately $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Syndax Pharmaceuticals by 18.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock worth $2,466,000 after purchasing an additional 30,596 shares during the period. Finally, Legal & General Group Plc raised its position in Syndax Pharmaceuticals by 4.9% during the 2nd quarter. Legal & General Group Plc now owns 84,575 shares of the company’s stock valued at $792,000 after purchasing an additional 3,937 shares in the last quarter.

Wall Street Analysts Forecast Growth

SNDX has been the subject of a number of recent research reports. BTIG Research reissued a “buy” rating and issued a $56.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, December 9th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Syndax Pharmaceuticals in a research note on Monday, October 27th. Barclays upped their target price on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. JPMorgan Chase & Co. dropped their price target on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Finally, Wall Street Zen raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $37.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.